Reports details

– where will opportunities lie in this diverse market with high, growing demand worldwide?

In 2009, the global pain relieving drug market generated revenues over $50bn. From 2010, that sector will benefit from new drugs and reformulations of existing products. Cases of pain from many conditions are increasing rapidly. Worldwide, the treatment of pain is a priority for healthcare providers, with high demand for drugs. Where is the pain relieving drug market heading - technologically and commercially - from 2010 onwards? 

Our new report - Global Pain Relieving Drug Market Analysis 2010-2025 - explains how this market will develop, and where the opportunities will lie. We show how you can benefit from its developments and potential. There remains unmet therapeutic needs in the treatment of pain. Many conditions have no pain relievers designed for relieving their symptoms, or very few. Side effects and safety constitute a challenge for drug developers. There is also increasing demand for pain treatments in developing countries. Novel compounds that show improved safety – with high efficacy – can gain significant market shares from 2010 onwards. There remain high revenues to be made in this sector from 2010 to 2025, our new report explains how you can benefit from this opportunity.

Global Pain Relieving Drug Market 2010-2025 covers the following therapeutic categories:
• Narcotics for pain
• NSAIDs for pain
• Treatments for arthritic pain
• Treatments for migraine
• Treatments for neuropathic pain
• Local anaesthetics.

What types of therapeutic agents are likely to enter the market from 2010 onwards, and will they dominate? Where do the main opportunities lie, and what are the drivers and restraints in this market? This report will provide you with the information that you need to understand current trends and future directions in the global pain drug market.

Comprehensive analysis of the global pain drug market

Global Pain Relieving Drug Market 2010-2025 examines that sector through a comprehensive review of information sources. We harness both primary and secondary research. This report provides unique sales forecasts, market share analyses, discussions of R&D pipeline developments and analyses of commercial drivers and restraints, including a SWOT analysis. There are 75 tables and figures included, as well as two original interviews with experts which are unavailable eslewhere. The result is a comprehensive market- and industry-centred study, with detailed analyses and informed opinion to benefit your work.

Why you should buy Global Pain Relieving Drug Market 2010-2025

This report gives you the following benefits in particular:
• You will review the current market for pain-relieving drugs
• You will analyse the overall pain drug market, including a global sales forecast for 2010 to 2025
• You will receive sales forecasts for pain submarkets from 2010 to 2025, with discussions
• You will receive sales forecasts for leading products from 2010 to 2025, with discussions of market potential and competition
• You will receive sales forecasts for leading geographical markets from 2010 to 2025, with discussions
• You will discover prospects for leading companies from 2010 onwards
• You will analyse the drivers, restraints, competition and opportunities influencing the pain drug sector
• You will discover the most-exciting R&D pipeline developments
• You will discover expert views from our survey, including full interview transcripts
• You will investigate under-met needs, with therapeutic requirements and commercial opportunities covered.

You can obtain this report today

Nobody with an interest in the pain relieving drug industry and market should overlook our new study. We predict that total revenues will increase during our forecast period. Rising prevalence of the many conditions associated with pain - coupled with high social and economic costs of pain - are therapeutic and commercial drivers of this market. Do you want to harness those opportunities? You can stay ahead by ordering this report today.

Gain an understanding of how to tap into the potential of this market by ordering Global Pain Relieving Drug Market Analysis 2010-2025 today.

Table Of Contents

Table of Contents
1. Executive Summary
1.1 The Pain Relieving Drug Market: Entering a Crucial Period
1.2 Aims, Scope and Format of the Report
1.3 Research and Analysis Methods

2. Introduction to Pain and its Treatment
2.1 What is Pain?
2.1.1 Historical Aspects of Pain
2.2 Pain Pathways
2.2.1 WHO Pain Ladder
2.3 Classification and Types of Pain
2.3.1 Acute Pain
2.3.2 Chronic Pain
2.3.2.1 Psychosocial Effects of Chronic Pain
2.3.2.2 The Financial Burden of Chronic Pain
2.3.2.3 Chronic Cancer Pain
2.3.2.4 Breakthrough Cancer Pain
2.4 Neuropathic Pain
2.4.1 Distinguishing Neuropathic Pain
2.5 Neurochemistry of Pain
2.5.1 Prostaglandins
2.5.2 Opioids
2.6 Pain Treatments
2.7 OTC Pain Relievers

3. The Global Pain Pharmaceutical Market 2010-2025
3.1 The Global Pain Market: Analysis and Forecast
3.2 Sub-Market Categories of the Global Pain Drug Market
3.2.1 Oxycontin Currently Leads the Global Pain Drug Market
3.2.2 The Anti-Epileptics Segment: Will its Success Last?
3.3 Success in the Pain Relieving Drug Market Has Proved Challenging
3.4 While the Past Has Been Difficult for Pain Management, There is Optimism for the Future

4. The Global Narcotics Market 2010-2025
4.1 The Narcotics Market Analysis and Forecast
4.2 Oxycontin - Therapeutic and Commercial Challenges
4.2.1 Development of Oxycontin (Oxycodone)
4.3 Duragesic (Fentanyl) - Challenges in the Market
4.3.1 Development of Duragesic (Fentanyl)
4.4 Fentanyl MYLA Will Show Strong Revenues
4.4.1 Fentanyl
4.5 Actiq Fighting a Decline in Sales
4.5.1 Actiq (Fentanyl Citrate)
4.6 Other Agents
4.7 Total Sales in the Narcotics Market Will Increase, Despite its Being Crowded

5. The Global Non-Narcotics Market 2010-2025
5.1 The Non-Narcotics Market Analysis and Forecast
5.2 Efferalgan is Currently the Non-Narcotic Market's Leading Drug
5.2.1 Development of Efferalgan (Paracetamol/Acetaminophen)
5.3 Tylenol - a Future Blockbuster of the Non-Narcotics Market?
5.3.1 Development of Tylenol (Paracetamol/Acetaminophen)
5.4 Doliprane (Paracetamol/Acetaminophen)
5.5 Will Advil Exhibit Strong Growth?
5.5.1 Advil (Ibuprofen)
5.6 Aspirin Bayer - Line Extensions Keeping Sales Up
5.6.1 Aspirin Bayer (Acetylsalicylic Acid)
5.7 Other Agents

6. The Global Arthritic Pain Drug Market 2010-2025
6.1 The Arthritic Pain Market Analysis and Forecast
6.1.1 Safety Issues for COX-2 Inhibitors
6.2 Pfizer's Celebrex Dominates the Market, but Will it Last?
6.2.1 Development of Celebrex (Celecoxib)
6.3 Voltaren Will Exhibit Strong Growth
6.3.1 Development of Voltaren (Diclofenac)
6.4 Arcoxia: Strong Growth over the Forecast Period?
6.4.1 Development of Arcoxia (Etoricoxib)
6.5 Loxonin: Sales in Developing Countries Aiding Growth
6.5.1 Loxonin (Loxoprofen)
6.6 Mobic Will Suffer from Generic Competition
6.6.1 Development of Mobic (Meloxicam)
6.7 Other Agents
6.8 Outlook for the Arthritis Pain Drug Market

7. The Global Migraine Market 2010-2025
7.1 The Migraine Drug Market Analysis and Forecast
7.2 GSK's Blockbuster Imitrex/Imigran Faces Revenue Decline
7.2.1 Development of Imitrex/Imigran (Sumatriptan)
7.3 Maxalt's Patent Expiry Will Affect Sales
7.3.1 Development of Maxalt (Rizatriptan)
7.4 Zomig's Decline in Sales
7.4.1 Development of Zomig (Zolmitriptan)
7.5 Relpax Will Exhibit Loss of Revenue from 2010-2025
7.5.1 Development of Relpax (Eletriptan)
7.6 Other Agents
7.7 What Does the Future Hold for Migraine Therapy?
7.8 Unmet Needs in the Treatment of Migraine

8. Neuropathic Pain and Local Anaesthetics Markets 2010-2025
8.1 Introduction
8.1.1 Anti-Epileptic Drugs Market
8.2 Anti-Epileptic Market Analysis and Forecast
8.2.1 Lyrica
8.2.2 The Development of Lyrica (Pregabalin)
8.2.3 Topamax (Topiramate): Impending Patent Expiry
8.2.4 Topamax: Challenges this Product has to Face
8.2.5 Other Agents
8.3 Local Anaesthetic Market Analysis and Forecast
8.3.1 Lidoderm (Lidocaine) Forecast
8.3.2 Lidoderm: Market Leader for the Local Anaesthetic Market
8.3.3 Other Agents

9. SWOT Analysis of the Global Pain Drug Market
9.1 SWOT Analysis
9.2 Market Drivers
9.3 Market Restraints
9.4 The Pain Market Suffered After the Withdrawal of COX-2 Inhibitors
9.5 Lack of Adequate Reimbursement Limits Potential of Pain Drugs
9.6 Patients Dependent on Reformulations of Existing Drugs
9.7 The Narcotics Market Suffers from Side Effects
9.8 Risk of Intestinal Bleeding Associated with NSAIDs
9.9 The Under-Treatment of Pain
9.10 How Will Those Findings Affect Commercial Prospects?
9.11 The Future of the Pain Market - Closing Comments
9.11.1 Improved Use of New and Existing Pain Management Therapies
9.11.2 Analgesic Effects of Established Drugs for Other Indications
9.11.3 Personalised Pain Management Therapy?

10. Geographical Breakdown of the Global Pain Market 2010-2025
10.1 The Pain Drug Market: Regional Sales Breakdown
10.2 Countries Leading the Global Pain Market, 2009
10.3 Pain Drug Sales in Major National Markets
10.3.1 The Pain Drug Market in the US
10.3.2 The Pain Drug Market in Germany
10.3.3 The Pain Drug Market in France
10.3.4 The Pain Drug Market in Japan
10.3.5 The Pain Drug Market in the UK
10.3.6 The Pain Drug Market in Canada
10.3.7 The Pain Drug Market in Spain
10.3.8 The Pain Drug Market in India
10.3.9 The Pain Drug Market in China

11. RandD Pipeline for the Treatment of Pain
11.1 The RandD Pipeline for the Pain Market is Large and Expanding
11.2 The Potential of the Pain Market Has Encouraged RandD
11.3 Innovation Rules for Early-Stage Pipeline Drugs
11.4 Late-Stage Pipeline Products in the Narcotics Sector
11.5 Late-Stage Pipeline Products in the Non-Narcotics Sector
11.6 Late-Stage Pipeline Products in the Anti-Arthritic Sector
11.7 Late-Stage Pipeline Products in the Anti-Migraine Sector
11.8 Late-Stage Pipeline Products in the Anti-Epileptic and Local Anaesthetic Sectors
11.9 The Pain Drug Pipeline Shows Short- and Long-Term Potential

12. Future Therapies
12.1 Cannabinoids and Pain: An Alternative to Opioids?
12.2 Experimentally-Induced Acute Pain
12.3 Post Surgical Acute Pain
12.4 Chronic Pain
12.5 Sativex
12.5.1 European Phase III Trials of Sativex
12.5.2 Sativex Approved for Cancer Pain
12.6 Cannabinoids and Pain: a Lucrative Market?
12.7 The Future of Pain Research
12.8 Advanced Drug Delivery
12.8.1 Delivery of Poorly-Soluble Drugs
12.8.2 Examples of Poorly-Soluble Drugs

13. Interviews with Experts
13.1 Interview with Dr William Schmidt (NorthStar Consulting LLC)
13.1.1 Growth of the Pain Market
13.1.2 New Targets in Pain Management
13.1.3 Unmet Needs in the Pain Market
13.1.4 Regulatory Hurdles in the Post-Vioxx Era
13.1.5 The Future of COX-2 Inhibitors
13.2 Interview with Dr Anastasia Liapi (Astellas Pharma Europe)
13.2.1 Assessing the Commercial Value of Novel Pain Therapies
13.2.2 Hurdles That Face New Launches in the Pain Market
13.2.3 Geographical Differences

14. Conclusions
14.1 The Pain Market is Achieving Sales Growth that Will Last
14.2 The Anti-Epileptics Market
14.3 The Narcotics Market
14.4 The Anti-Arthritic Market
14.5 The Anti-Migraine Market
14.6 Major Success in the Pain Drug Market Has Proved Challenging
14.7 Why Growth of the Pain Relieving Drug Market Will Continue

List of Tables

Table 3.1 The Global Pain Drug Market: Sales Forecast ($m), 2009-2017
Table 3.2 The Global Pain Drug Market: Sales Forecast ($m), 2018-2025
Table 3.3 The Global Pain Drug Market: Sales ($m) and Market Shares (%) Forecasts 2009-2017
Table 3.4 The Global Pain Drug Market: Sales ($m) and Market Shares (%) Forecasts 2018-2025
Table 3.5 Top Ten Products in the Global Pain Treatments Market: Sales ($m), 2009
Table 4.1 The Global Narcotics Market: Sales Forecasts ($m), 2009-2017
Table 4.2 The Global Narcotics Market: Sales Forecasts ($m), 2018-2025
Table 5.1 The Global Non-Narcotics Market: Sales Forecasts ($m), 2009-2017
Table 5.2 The Global Non-Narcotics Market: Sales Forecasts ($m), 2018-2025
Table 6.1 The Global Anti-Arthritic Market: Sales Forecasts ($m), 2009-2017
Table 6.2 The Global Anti-Arthritic Market: Sales Forecasts ($m), 2018-2025
Table 7.1 The Global Anti-Migraine Market: Sales Forecasts ($m), 2009-2017
Table 7.2 The Global Anti-Migraine Market: Sales Forecasts ($m), 2018-2025
Table 8.1 The Global Anti-Epileptics Market: Sales Forecasts ($m), 2009-2017
Table 8.2 The Global Anti-Epileptics Market: Sales Forecasts ($m), 2018-2025
Table 8.3 The Global Local Anaesthetic Market: Sales Forecasts ($m), 2009-2017
Table 8.4 The Global Local Anaesthetic Market: Sales Forecasts ($m), 2018-2025
Table 9.1 SWOT Chart for the Global Pain Drug Market, 2010
Table 10.1 Global Pain Market Revenues ($m) and Shares (%) by Region, 2009
Table 10.2 Countries Leading the Pain Drug Market ($m), 2009
Table 10.3 Pain Market Sales Forecasts for the Leading Seven Countries ($m), 2009-2017
Table 10.4 Pain Market Sales Forecasts for the Leading Seven Countries ($m), 2018-2025
Table 10.5 Seven Major Country Market Shares (%), 2009, 2015 and 2025
Table 11.1 Late-Stage Narcotic Pipeline Agents, 2010
Table 11.2 Late-Stage Narcotic Pipeline Agents, 2010 (Continued)
Table 11.3 Late-Stage Non-Narcotic Pipeline Agents, 2010
Table 11.4 Late-Stage Non-Narcotic Pipeline Agents, 2010 (Continued)
Table 11.5 Late-Stage Anti-Arthritic Pipeline Agents, 2010
Table 11.6 Late-Stage Anti-Migraine Pipeline Agents, 2010
Table 11.7 Late-Stage Anti-Epileptic Pipeline Agents, 2010
Table 11.8 Late-Stage Local Anaesthetic Pipeline Agents, 2010

List of Figures

Figure 3.1 The Global Pain Drug Market: Sales Forecast ($m), 2010-2025
Figure 3.2 Leading Pain Market Segments: Sales Forecasts ($m), 2010-2025
Figure 3.3 Leading Pain Market Segments: Sales ($m) and Market Shares (%), 2009, 2015, 2010 and 2015
Figure 3.4 Leading Pain Markets: Market Shares (%), 2009
Figure 3.5 Leading Pain Markets' Market Shares (%), 2025
Figure 4.1 The Global Narcotics Market: Sales Forecast ($m), 2010-2025
Figure 4.2 Oxycontin Sales Forecast ($m), 2010-2025
Figure 4.3 Duragesic Sales Forecast ($m), 2010-2025
Figure 4.4 Fentanyl Myla Sales Forecast ($m), 2010-2025
Figure 4.5 Actiq Sales Forecast ($m), 2010-2025
Figure 4.6 Other Products: Sales Forecast ($m), 2010-2025
Figure 5.1 The Global Non-Narcotics Market: Sales Forecast ($m), 2010-2025
Figure 5.2 Efferalgan Sales Forecast ($m), 2010-2025
Figure 5.3 Tylenol Sales Forecast ($m), 2010-2025
Figure 5.4 Doliprane Sales Forecast ($m), 2010-2025
Figure 5.5 Advil Sales Forecast ($m), 2010-2025
Figure 5.6 Aspirin Bayer Sales Forecast ($m), 2010-2025
Figure 5.7 Others Agents: Sales Forecast ($m), 2010-2025
Figure 6.1 The Global Anti-Arthritic Market: Sales Forecast ($m), 2010-2025
Figure 6.2 Celebrex: Sales Forecast ($m), 2010-2025
Figure 6.3 Voltaren: Sales Forecast ($m), 2010-2025
Figure 6.4 Arcoxia: Sales Forecast ($m), 2010-2025
Figure 6.5 Loxonin: Sales Forecast ($m), 2010-2025
Figure 6.6 Mobic: Sales Forecast ($m), 2010-2025
Figure 6.7 Others Agents: Sales Forecast ($m), 2010-2025
Figure 7.1 The Global Anti-Migraine Market: Sales Forecast ($m), 2010-2025
Figure 7.2 Imitrex/Imigran Sales Forecast ($m), 2010-2025
Figure 7.3 Maxalt Sales Forecast ($m), 2010-2025
Figure 7.4 Zomig Sales Forecast ($m), 2010-2025
Figure 7.5 Relpax Sales Forecast ($m), 2010-2025
Figure 7.6 Other Agents: Sales Forecast ($m), 2010-2025
Figure 8.1 Global Anti-Epileptic Market: Sales Forecast ($m), 2010-2025
Figure 8.2 Lyrica Sales Forecast ($m), 2010-2025
Figure 8.3 Topamax Sales Forecast ($m), 2010-2025
Figure 8.4 Others Agents: Sales Forecast ($m), 2010-2025
Figure 8.5 Global Local Anaesthetic Sales Forecast ($m), 2010-2025
Figure 8.6 Lidoderm Sales Forecast ($m), 2010-2025
Figure 8.7 Other Agents: Sales Forecast ($m), 2010-2025
Figure 10.1 Global Pain Market Shares (%) by Region, 2009
Figure 10.2 Countries Leading the Global Pain Market ($m), 2009
Figure 10.3 US, Germany and Other Countries: Sales Forecasts ($m), 2010-2025
Figure 10.4 European, Canadian and Japanese Sales Forecasts ($m), 2010-2025
Figure 10.5 Global Pain Market Shares (%) by Country, 2009
Figure 10.6 Global Pain Market Shares (%) by Country, 2015
Figure 10.7 Global Pain Market Shares (%) by Country, 2025 

Companies Listed
AstraZeneca
Abbott Laboratories
Acura Pharmaceuticals
Alpharma Pharmaceuticals
Alza Corporation
Almirall
Anesiva
Anesta Corporation
Apotex
Applied Pharma Research
Archimedes Pharma
Astellas Pharma
Bayer HealthCare Pharmaceuticals
Biovail Corporation
Boehringer Ingelheim
Bristol Myers Squibb
Cephalon
Cipher Pharmaceuticals
CyDex Pharmaceuticals
Daiichi Sankyo
Dr. Reddy’s Laboratories
DURECT Corporation
Eisai
EMEA
Endo Laboratories
Epicept Corporation
Ethypharm
Eurand Pharmaceuticals
FDA
Genentech
Gruenenthal
GlaxoSmithKline
GW Pharmaceuticals
Health Canada
Hisamitsu Pharmaceutical
Horizon Therapeutics
International Association for the Study of Pain (IASP)
Ikano Therapeutics
Janssen Pharmaceutical
Javelin Pharmaceuticals
Johns Hopkins University
Johnson and Johnson
King Pharmaceuticals
Kowa Pharmaceuticals
Kyorin Pharmaceutical
Labopharm
Lundbeck Pharmaceuticals
MAP Pharmaceuticals
Meda Pharmaceuticals
Merck and Co.
Mylan Pharmaceuticals
Napp Pharmaceutical Group
National Institutes of Health (NIH)
NicOx
NorthStar Consulting LLC
Novartis
NuPathe
Ono Pharmaceutical Company
Pacira Pharmaceuticals
Pain Therapeutics
Paion
Pfizer
Plethora Solutions
PLx Pharma
Pozen Pharmaceuticals
Purdue Pharma
QRxPharma
Ranbaxy Laboratories
Ratiopharm
Recordati Pharmaceuticals
Roxro Pharma
Sanofi-Aventis
Shionogi Pharma
SK Corporation
SkyePharma
STADA Pharmaceuticals
Symbollon Pharmaceuticals
Teva Pharmaceutical Industries
UCB Pharma
US Society for Neuroscience
Valeant Pharmaceuticals
WEX Pharmaceuticals
Winston Pharmaceuticals
World Health Organisation (WHO)
Wyeth Pharmaceuticals
ZARS Pharma
Zogenix

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

Antibiotics: Technologies and Global Markets

Antibiotics: Technologies and Global Markets

  • $ 6 650
  • Industry report
  • May 2014
  • by BCC Research

Use this report to: - Identify the major market trends and the factors driving or inhibiting the growth of the global pharmaceutical antibiotics market and its various submarkets. - Learn about developments ...

Antifungal Drugs : Technologies and Global Markets

Antifungal Drugs : Technologies and Global Markets

  • $ 6 650
  • Industry report
  • June 2014
  • by BCC Research

This report aims to determine the current status of the global human antifungal market and assess its growth potential over the five-year period from 2013 through 2018. It covers approved human therapeutics ...

DNA Vaccines: Technologies and Global Markets

DNA Vaccines: Technologies and Global Markets

  • $ 6 650
  • Industry report
  • July 2014
  • by BCC Research

This BCC Research study determines the specific applications and global market demand for DNA vaccine products over a five-year period from 2014 to 2019. High growth and market potential segments of the ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.